Key result
Simvastatin, but not fenofibrate, lowered C-reactive protein by 32% on day 3 (p<0.001) and reduced platelet activation, while both drugs showed early antithrombotic and anti-inflammatory effects.
Why the study?
Does simvastatin compared to fenofibrate improve markers of inflammation, thrombin formation, and platelet activation in patients with hypercholesterolemia at high risk of CAD?
Population
42 patients with high risk of coronary artery disease and LDL cholesterol >130 mg/dl
Comparison
Simvastatin 40 mg/d for 28 days vs Micronised fenofibrate 160 mg/d for 28 days
Design
RCT, randomized, double-blind
Follow-up
28 days
Authors
Loading...
Simvastatin may be preferred over fenofibrate for rapid CRP and platelet effects in high-risk hypercholesterolemia; extends evidence for early differential pleiotropic actions.
RCT (n=42)
Double-blind
randomized
Does simvastatin compared to fenofibrate improve markers of inflammation, thrombin formation, and platelet activation in patients with hypercholesterolemia at high risk of CAD?
p-value: p=<0.001
Statins and fibrates exert rapid anti-inflammatory and antithrombotic effects within 3 days of therapy, but only statins appear to inhibit platelet function early on.
Undas et al. (2005) conducted an RCT in Hypercholesterolemia (n=42). Simvastatin vs. Micronised fenofibrate (160 mg/d) was evaluated on C-reactive protein (CRP) reduction on day 3 (p=<0.001). Simvastatin, but not fenofibrate, lowered C-reactive protein by 32% on day 3 (p<0.001) and reduced platelet activation, while both drugs showed early antithrombotic and anti-inflammatory effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: